Long-Term Prophylaxis for Hereditary Angioedema: Real-World Treatment Patterns in Selected US Allergy Clinics
International Archives of Allergy and Immunology · 21.05.2026 · 1-6
DOI: 10.1159/000551984 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Archives of Allergy and Immunology, online erschienen am 21.05.2026. Verfasst von Jason Raasch und 7 weiteren Autor:innen. Beteiligte Einrichtung: Midwest Immunology, Plymouth, Minnesota, USA. Die Arbeit nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Hereditary angioedema (HAE) is a rare genetic disorder which causes recurrent and unpredictable swelling attacks that pose high morbidity and risk of death. Long-term prophylactic (LTP) treatments are an important clinical management tool to reduce attack frequency. This study aims to assess real-world treatment patterns among US patients receiving LTP therapy.
Methods
The Patient Important Outcomes National Data Repository for Hereditary Angioedema (PIONEER) HAE registry contains structured and unstructured data for patients within the Consortium of Independent Immunology Clinics (CIIC). Eligibility criteria included diagnosis of HAE due to C1-inhibitor deficiency (HAE-C1NH), observation between April 2021 and March 2024 and record of a LTP therapy. Index therapy was defined as the earliest prophylactic therapy for which the patient had at least 180 days of medical history prior to initiation and 180 days of follow-up thereafter. Patients were observed for up to 3 years.
Results
This study included 179 patients; most had HAE-C1INH Type 1 (86%) with median age 38 years (IQR: 25–53). Index therapy included kallikrein inhibitors (55%), C1-esterase inhibitors (37%), androgens (6%), and antifibrinolytic agents (2%); most often initiated in 2019 (21%). Eighty-three (46%, 83/179) discontinued index therapy, with a median 12 (IQR: 4.8–33) months to discontinuation. Discontinuations were most commonly due to lack of efficacy (29%, 22/76). Of those, 48/83 (58%) switched or restarted prophylactic therapy.
Conclusion
Nearly half of patients discontinued their index LTP at some point during the observation period, primarily due to efficacy, administration, or dosing challenges. Advanced understanding of unmet treatment needs and other important factors in the HAE treatment landscape will require more robust and detailed data on real-world treatment decision-making.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Midwest Immunology, Plymouth, Minnesota, USA.
- Institute for Asthma and Allergy, Chevy Chase, Maryland, USA.
- Department of Medicine, Division of Allergy and Immunology, University of California San Diego, San Diego, California, USA.
- Trio Health Inc., Louisville, Colorado, USA, valeria.duran@triohealth.com.
- Ionis Pharmaceuticals Inc., Carlsbad, California, USA.
Zitieren
APA
Raasch, J., Li, H., Riedl, M. A., Duran, V., Flick, E. D., Ruggles, J., Schnabel, C. A., & Villa, K. F. (2026). Long-Term Prophylaxis for Hereditary Angioedema: Real-World Treatment Patterns in Selected US Allergy Clinics. International Archives of Allergy and Immunology, 1-6. https://doi.org/10.1159/000551984
Vancouver
Raasch J, Li H, Riedl MA, Duran V, Flick ED, Ruggles J, et al. Long-Term Prophylaxis for Hereditary Angioedema: Real-World Treatment Patterns in Selected US Allergy Clinics. International Archives of Allergy and Immunology. 2026:1-6. doi:10.1159/000551984
BibTeX
@article{Raasch2026,
author = {Raasch, Jason and Li, Henry and Riedl, Marc A and Duran, Valeria and Flick, E Dawn and Ruggles, James and Schnabel, Catherine A and Villa, Kathleen F},
title = {Long-Term Prophylaxis for Hereditary Angioedema: Real-World Treatment Patterns in Selected US Allergy Clinics},
journal = {International Archives of Allergy and Immunology},
year = {2026},
pages = {1--6},
doi = {10.1159/000551984}
}
EUVIMED